EyePoint announced it has commercially launched Yutiq in the United States. Yutiq is the company’s FDA approved, three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The product is available for ordering and delivery to physicians. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in need of financial assistance.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.